Abstract
Viral infections cause morbidity and mortality in allogeneic HSCT recipients. To treat the underlying problem, namely lack of antigen-specific T cells, we and others have successfully generated and infused adoptive T-cell lines specific for EBV, CMV and Adenovirus. We have shown that as few as 2 × 105/kg trivirus-specific cytotoxic T lymphocytes (CTL) proliferated by several logs post-infusion and appeared to protect the recipients against all three viruses. Despite the encouraging clinical results, broader implementation of the approach is limited by (i) the usage of infectious virus material (EBV/Adv) and (ii) the prolonged culture (3 months for EBV-LCL production and CTL stimulation).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
